New tests for trials of very few patients using longitudinal data - a case-study in Autosomal Recessive Cerebellar Ataxias
Hendrickx, N.; Mentre, F.; Karlsson, M. O.; Hooker, A. C.; Traschütz, A.; Schüle, R.; PROSPAX Consortium, ; EVIDENCE-RND Consortium, ; Synofzik, M.; Comets, E.
Show abstract
We propose two new tests to detect drug effects (DE) in trials of one to very few patients followed during two periods (before and after initiation of a treatment). Both methods use longitudinal natural history data to inform the estimation of each patient's DE. The first method uses a non linear mixed effect model (NLMEM) reflecting an expected natural history with a hypothetical drug effect, to estimate the Conditional Distribution of the Drug Effect (CDDE). The second method trains a Pareto Depth Analysis (PDA) algorithm, a machine learning based approach based on outlier detection, that we implement using data simulated under the NLMEM. We evaluated the two tests with a simulation study. We used data from the PROSPAX study in Autosomal Recessive Cerebellar Ataxias (ARCAs, to derive a NLMEM for the Scale for the Assessment and Rating of Ataxia score. The CDDE method provided controlled type I error and, in some scenarios, adequate corrected power, though sensitivity analyses showed vulnerability to misspecification. The PDA method demonstrated lower statistical power except with high score precision. These results highlight different strategies for quantifying treatment effects in ultra rare, patient' specific trials. They can inform methodological design for future ARCA precision therapies.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score 95%
- Prediction-powered Inference for Clinical Trials 91%
- Comparison of Bayesian networks, G-estimation and linear models to estimate causal treatment effects in aggregated N-of-1 trials 91%
Similar papers in this journal
- Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson’s Disease 91%
- Simulating clinical trials for model-informed precision dosing: Using warfarin treatment as a use case 90%
- Informing Pharmacokinetic Models with Physiological Data: Oral Population Modeling of L-Serine in Humans 89%
Similar papers in this journal
- Clinical Trials for Wolfram Syndrome Neurodegeneration: Novel Design, Endpoints, and Analysis Models 92%
- Using the Bayesian credible subgroups method to identify populations benefiting from treatment: An application to the Look AHEAD trial 92%
- Significant Relaxation of SARS-CoV-2-Targeted Non-Pharmaceutical Interventions Will Result in Profound Mortality: A New York State Modelling Study 90%
Similar papers in this journal
- Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: a scoping review 91%
- A modular pipeline for natural language processing-screened human abstraction of a pragmatic trial outcome from electronic health records 90%
- Use of estimands in cluster randomised trials: a review 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.